Elevation of fetal hemoglobin is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC leukemia group, gimema and german MDS study group
Julia Stomper(Dana-Farber Cancer Institute), Michael Lübbert(University of Freiburg), Mario Luppi(University of Modena and Reggio Emilia), Robin Foà(Sapienza University of Rome), Walter J. F. M. van der Velden(Radboud University Nijmegen), Frédéric Baron(University of Liège), Joop H. Jansen(Radboud University Nijmegen), Sylvain Chantepie(Centre Hospitalier Universitaire de Caen Normandie), Mels Hoogendoorn(Medisch Centrum Leeuwarden), Marjolein van der Poel(Maastricht University), Tobias Ma(University Medical Center Freiburg), Michal Kiciński(European Organisation for Research and Treatment of Cancer), Gerwin Huls(University Medical Center Groningen), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Andreas Neubauer(RWTH Aachen University), Thomas Meyer(University Medical Center Freiburg), Radovan Vrḫovac(University Hospital Centre Zagreb), Laimonas Griškevičius(Vilnius University), Richard Noppeney(Essen University Hospital), Ernesta Audisio(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Pierre W. Wijermans(Radboud University Nijmegen), Stéphanie Antunes(European Organisation for Research and Treatment of Cancer), Adriano Venditti(University of Rome Tor Vergata), Anna Candoni(University of Udine)
Cited by 0
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k